T2 Biosystems Stock Performance
| TTOO Stock | USD 0 0.0005 25.00% |
T2 Biosystems holds a performance score of 12 on a scale of zero to a hundred. The firm owns a Beta (Systematic Risk) of -4.94, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning T2 Biosystems are expected to decrease by larger amounts. On the other hand, during market turmoil, T2 Biosystems is expected to outperform it. Use T2 Biosystems information ratio and the relationship between the value at risk and period momentum indicator , to analyze future returns on T2 Biosystems.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in T2 Biosystems are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of very fragile basic indicators, T2 Biosystems displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
TTOO |
T2 Biosystems Relative Risk vs. Return Landscape
If you would invest 1.10 in T2 Biosystems on October 31, 2025 and sell it today you would lose (0.85) from holding T2 Biosystems or give up 77.27% of portfolio value over 90 days. T2 Biosystems is currently generating 21.7789% in daily expected returns and assumes 141.7708% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than TTOO, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
T2 Biosystems Target Price Odds to finish over Current Price
The tendency of TTOO Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0 | 90 days | 0 | more than 94.0 |
Based on a normal probability distribution, the odds of T2 Biosystems to move above the current price in 90 days from now is more than 94.0 (This T2 Biosystems probability density function shows the probability of TTOO Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days T2 Biosystems has a beta of -4.94. This usually implies as returns on its benchmark rise, returns on holding T2 Biosystems are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, T2 Biosystems is expected to outperform its benchmark. In addition to that T2 Biosystems has an alpha of 22.4902, implying that it can generate a 22.49 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). T2 Biosystems Price Density |
| Price |
Predictive Modules for T2 Biosystems
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as T2 Biosystems. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.T2 Biosystems Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. T2 Biosystems is not an exception. The market had few large corrections towards the T2 Biosystems' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold T2 Biosystems, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of T2 Biosystems within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 22.49 | |
β | Beta against Dow Jones | -4.94 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | 0.15 |
T2 Biosystems Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of T2 Biosystems for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for T2 Biosystems can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| T2 Biosystems is way too risky over 90 days horizon | |
| T2 Biosystems has some characteristics of a very speculative penny stock | |
| T2 Biosystems appears to be risky and price may revert if volatility continues | |
| T2 Biosystems has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7.19 M. Net Loss for the year was (50.08 M) with loss before overhead, payroll, taxes, and interest of (24.77 M). | |
| T2 Biosystems currently holds about 13.21 M in cash with (48.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 74.0% of the company shares are owned by institutional investors |
T2 Biosystems Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of TTOO Pink Sheet often depends not only on the future outlook of the current and potential T2 Biosystems' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. T2 Biosystems' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.6 M | |
| Cash And Short Term Investments | 15.7 M |
T2 Biosystems Fundamentals Growth
TTOO Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of T2 Biosystems, and T2 Biosystems fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TTOO Pink Sheet performance.
| Return On Equity | -6.22 | |||
| Return On Asset | -0.9 | |||
| Operating Margin | (4.91) % | |||
| Current Valuation | 21.91 M | |||
| Shares Outstanding | 21.04 M | |||
| Price To Earning | (2.04) X | |||
| Price To Book | 14.50 X | |||
| Price To Sales | 0.69 X | |||
| Revenue | 7.19 M | |||
| EBITDA | (43.88 M) | |||
| Cash And Equivalents | 13.21 M | |||
| Cash Per Share | 1.87 X | |||
| Total Debt | 49.5 M | |||
| Debt To Equity | 6.64 % | |||
| Book Value Per Share | (6.91) X | |||
| Cash Flow From Operations | (48.14 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 34.8 M | |||
| Retained Earnings | (584.3 M) | |||
| Current Asset | 77.78 M | |||
| Current Liabilities | 18.54 M | |||
About T2 Biosystems Performance
By examining T2 Biosystems' fundamental ratios, stakeholders can obtain critical insights into T2 Biosystems' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that T2 Biosystems is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts. T2 Biosystems operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 182 people.Things to note about T2 Biosystems performance evaluation
Checking the ongoing alerts about T2 Biosystems for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for T2 Biosystems help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| T2 Biosystems is way too risky over 90 days horizon | |
| T2 Biosystems has some characteristics of a very speculative penny stock | |
| T2 Biosystems appears to be risky and price may revert if volatility continues | |
| T2 Biosystems has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7.19 M. Net Loss for the year was (50.08 M) with loss before overhead, payroll, taxes, and interest of (24.77 M). | |
| T2 Biosystems currently holds about 13.21 M in cash with (48.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 74.0% of the company shares are owned by institutional investors |
- Analyzing T2 Biosystems' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether T2 Biosystems' stock is overvalued or undervalued compared to its peers.
- Examining T2 Biosystems' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating T2 Biosystems' management team can have a significant impact on its success or failure. Reviewing the track record and experience of T2 Biosystems' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of T2 Biosystems' pink sheet. These opinions can provide insight into T2 Biosystems' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in TTOO Pink Sheet
T2 Biosystems financial ratios help investors to determine whether TTOO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in TTOO with respect to the benefits of owning T2 Biosystems security.